Clinical dry mouth often goes undetected as patients adjust to xerostomia and symptoms develop gradually, making hyposalivation a low priority for many healthcare professionals. Methods used to objectively measure saliva, such as collecting drooled saliva, can be unappealing to both patients and staff.
FishburneTabs®OH, developed by Fishburne May LLC, is now available as a saliva volume indicator intended for use by medical and dental professionals. According to the company, the tool is designed to make hyposalivation screening reliable and efficient.
Dry mouth significantly increases the risk of oral health problems and is often an early indicator of systemic diseases, including autoimmune disorders and diabetes, according to the company. Hyposalivation is associated with common medications, cannabinoids, autoimmune diseases, diabetes, and stress. The risk is amplified in older adults and in patients taking multiple medications.
FishburneTabs®OH measure total saliva from all salivary glands with a three-minute test. The test can be repeated to monitor changes and individual trends in saliva volume. According to the company, the patented technology is based on specialized paper, a design intended to ensure consistent placement in the mouth, and natural capillary action. Saliva is absorbed into the paper device and remains unseen.
Invented by a dentist, the tool is intended to support both physicians and oral health professionals in evaluating and monitoring patients when systemic disease is pre-existing or suspected, according to the company. Reimbursement opportunities are available through Medicare and some insurers.
FishburneTabs®OH are now available from Cardinal Health. More information is available at https://www.cardinalhealth.com/en.htm.
